Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
12:30pm, Wednesday, 08'th Jan 2025
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in Febr
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
11:06am, Tuesday, 07'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
10:51am, Tuesday, 24'th Dec 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:40am, Wednesday, 18'th Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:03am, Monday, 16'th Dec 2024
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?
06:49am, Monday, 09'th Dec 2024
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
03:26pm, Monday, 02'nd Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
11:01am, Wednesday, 27'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
08:03am, Tuesday, 19'th Nov 2024
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
10:51am, Friday, 15'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
08:03am, Wednesday, 13'th Nov 2024
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
08:51am, Monday, 11'th Nov 2024
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
08:21am, Friday, 08'th Nov 2024
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
11:30am, Thursday, 07'th Nov 2024
Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.
